<DOC>
	<DOCNO>NCT01968798</DOCNO>
	<brief_summary>The ASPREE Cancer Endpoint Study ( ACES ) , ancillary study ASPirin Prevention Events Elderly ( ASPREE ) Study , allow examination effect daily low-dose aspirin ( 100 mg ) compare placebo , specific DNA biomarkers select specific incident recurrent cancer metastasis . The establishment ACES biobank allow exploration DNA-related molecular mechanism aspirin 's protective effect cancer , cancer associate mortality metastasis , use blood saliva DNA specimens , urine , tumor tissue .</brief_summary>
	<brief_title>ASPREE Cancer Endpoints Study</brief_title>
	<detailed_description>The ASPREE Cancer Endpoint Study ( ACES ) ancillary study ASPirin Prevention Events Elderly ( ASPREE ) Study , 5 year randomize placebo- control trial 100 mg daily aspirin 19,000 elderly Australia US determine whether benefit low dose daily aspirin outweigh bleeding risk . The primary outcome ASPREE define prolongation `` disability-free life '' , measure survival without physical disability dementia . At present , primary purpose ACES : 1 ) collect information participant cancer screening , cancer diagnosis , family history cancer 2 ) establish biologic specimen repository ( biobank ) DNA tumor tissue , urine ASPREE large healthy age population US Australia future use ASPREE , NIA NCI investigator , academician broader research community . At time future separate application , store blood saliva , urine , tumor tissue , together information obtain participant ( relation health , lifestyle circumstance ) analyze address specific question regard association biomarkers major health outcome include cancer .</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Open Only Participants Parent ASPREE study 1 . Inclusion criterion : Men woman 65 year old US ( African American Hispanic ) , 70 year age Australia ( Caucasian , Asian , minority ) . Based NIAs discretion , select US site may recruit Caucasians 70 old 75 old . 2 . Exclusion criterion : ( please see www.ASPREE.org detailed list exclusion criterion ) . History diagnose dementia score &lt; 78 Modified Mini Mental State Exam second prerandomization ( baseline ) visit . ii . Disability , define dependence one Katz activity daily live . iii . Cardiovascular event , intercurrent illness likely cause death within next 5 year , current recurrent condition high risk major bleeding , e.g . cerebral aneurysm , cerebral AV malformation , bleed diathesis , recent peptic ulcer liver disease . iv . Anemia , i.e . hemoglobin level normal value ( male : 12 g/dL , female : 11 g/dL ) . 3 . Participants eligible ASPREE Cancer Endpoints Study ( ACES ) include participant recruit parent ASPREE study United States Australia . ACES participant ask consent : . Collection storage blood saliva DNA sample urine data future use . If ASPREE participant unwilling contribute biological sample , way jeopardize continue enrolment ASPREE . ii . Collection cancer tumor specimens storage data future use .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ACES</keyword>
	<keyword>ASPREE Cancer Endpoints Study</keyword>
	<keyword>Cancer</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Tumor</keyword>
</DOC>